Latest Breaking News On - Johnson innovative - Page 1 : vimarsana.com

Contineum Therapeutics Announces Appointment of John Healy as General Counsel & Corporate Secretary

Contineum Therapeutics, Inc. , a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with.

Contineum Therapeutics Announces Appointment of John Healy as General Counsel & Corporate Secretary

SAN DIEGO (BUSINESS WIRE) Jun 3, 2024

RYBREVANT®▼ (amivantamab) plus lazertinib shows longer

Johnson & Johnson to Obtain Rights to a Clinical-Stage Bispecific Antibody to Address Distinct Patient Needs in Atopic Dermatitis

The Company1 enters agreement with Numab Therapeutics to acquire its wholly owned subsidiary2 for the global rights to NM26, a Phase 2-ready investigational, first-in-class bispecific antibody.

J&J to Acquire Skin Disease Treatment Rights from Numab in $1.25 Billion Deal

By Denny Jacob Johnson & Johnson entered into an agreement with Numab Therapeutics to acquire the global rights for bispecific antibody NM26 in an all-cash deal valued at $1.25 billion. .

J&J Adds Another Bispecific Antibody for Atopic Dermatitis With $1.25B Acquisition

Johnson & Johnson : advances leadership in oncology innovation with more than 75 clinical study and real-world presentations at ASCO and EHA

Media contacts: Investor contact: .

Progressing personalised cell therapies in oncology

This article discusses the current landscape of CAR T therapies and highlights the potential of a novel BCMA-targeted oncology treatment.

Contineum Therapeutics Announces Appointment of Troy Ignelzi to Board of Directors

Contineum Therapeutics, Inc. , a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with.

Johnson & Johnson To Acquire Early-Stage Eczema Treatment Developer Proteologix For $850M - Johnson & Johnson (NYSE:JNJ)

Johnson & Johnson acquires Proteologix for $850 million, expanding its bispecific antibody portfolio for immune-mediated diseases.